Grünenthal Signed Joint Venture Collaboration Agreement with Kyowa Kirin to Establish Medicines Portfolio
Shots:
- Kyowa Kirin to receive ~$83.35M up front & an additional fee upon purchase of the remaining share & IP of the portfolio along with royalties. The transaction is expected to be close in Q2’23
- Grünenthal will hold a 51% majority share in the new company & get an option to acquire the remaining shares after Jan 2026. Kyowa Kirin will own a 49% share & will initially retain the IP related to the portfolio
- 13 brands from 6 therapeutic areas are included in the JV collaboration primarily focused on pain management which incl.: Abstral & PecFent for cancer pain, Moventig for opioid-induced constipation, and Adcal-D3 for osteoporosis. The portfolio is available in 7 EU markets through affiliates & in multiple additional territories globally through a network of partners
Ref: Businesswire | Image: Kyowa Kirin
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
